Omvoh®

Description

Omvoh® (mirikizumab-mrkz)

Omvoh® is a targeted biologic therapy designed to help adults with moderate-to-severe ulcerative colitis and Crohn’s disease achieve long-term inflammation control and symptom relief.

Powered by advanced IL-23 inhibition technology, Omvoh works by selectively blocking the inflammatory pathway responsible for chronic intestinal inflammation, helping reduce flare-ups and support intestinal healing. (European Medicines Agency (EMA))

Key Benefits

• Helps reduce intestinal inflammation and disease activity
• Designed for moderate-to-severe ulcerative colitis and Crohn’s disease
• Supports clinical remission and long-term symptom control
• Targets the IL-23 inflammatory pathway
• Available as both IV induction therapy and maintenance injections
• Precision biologic treatment for patients who have not responded well to other therapies (European Medicines Agency (EMA))

How It Works

Omvoh contains mirikizumab-mrkz, an IL-23p19 antagonist that selectively blocks interleukin-23 (IL-23), a key immune system protein involved in inflammatory bowel disease. By reducing IL-23 activity, Omvoh helps calm immune-driven inflammation in the digestive tract. (Omvoh)

Indications

Omvoh is approved for adults with:

• Moderately to severely active ulcerative colitis (UC)
• Moderately to severely active Crohn’s disease (CD) (MedLibrary.org)

Administration

• Initial treatment begins with intravenous (IV) infusions
• Followed by subcutaneous maintenance injections every 4 weeks
• Self-injection may be possible after healthcare provider training (European Medicines Agency (EMA))

Why Choose Omvoh

Omvoh offers a modern biologic approach that specifically targets the IL-23 inflammatory pathway without broadly suppressing the immune system. It provides a precision-focused option for patients seeking improved long-term control of inflammatory bowel disease symptoms. (Omvoh)

Important Safety Information

Common side effects may include:

• Upper respiratory infections
• Injection site reactions
• Headache
• Joint pain
• Rash

Serious risks may include allergic reactions and infections. Patients should be evaluated for tuberculosis and infections before starting treatment. (European Medicines Agency (EMA))